权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Skin Vaccination Against Influenza in the Young And Aged

年轻人和老年人的流感皮肤疫苗接种

基本信息

批准号：
8886505
负责人：
RICHARD W COMPANS
金额：
$ 70.29万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-02-06 至 2020-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8886505
关键词：
Adult Animal Model Animals Antigen-Presenting Cells Antigens Attenuated Live Virus Vaccine B-Lymphocytes Cavia Cells Cessation of life Characteristics Child Data Effectiveness Elderly Environment Exhibits FDA approved Goals Hospitalization Human Immune Immune response Immune system Immunity Immunization Individual Infection Inflammatory Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H7N9 Subtype Influenza vaccination Intramuscular Morbidity - disease rate Mus Population Population Group Population Heterogeneity Public Health Regulation Relative (related person)Research Risk Role Route Signal Transduction Site Skin Skin Aging Subunit Vaccines T cell response Technology Up-Regulation Vaccination Vaccine Research Vaccines Virus Virus Diseases adaptive immunity aged chemokine cytokine design experience global health group support high risk immunogenicity immunosenescence improved influenza outbreak influenza virus vaccine influenzavirus insight mortality mouse model nonhuman primate pandemic disease prevent public health relevance senescence uptake vaccination strategy vaccine delivery vaccine development vaccine efficacy

项目摘要

DESCRIPTION (provided by applicant): It is widely recognized that the young and elderly represent two population groups at high risk from influenza virus infection. Morbidity and mortality from influenza-related illness and secondary complications are highest in these groups. Although current influenza vaccines are relatively effective in eliciting protective immune responses in adults, they only confer limited protective immunity in the young and aged. The reasons for the reduced efficacy in these groups could be a result of various factors including reduced potency/immunogenicity of split and subunit influenza vaccines, the lack of prior exposure and immaturity of the immune system observed in young individuals and the immunosenescence observed in the elderly. The current intramuscular route used to administer these vaccines may also be less effective for antigen uptake and presentation due to the reduced interaction with MHC II immune cells, thus limiting the magnitude of the immune responses. In order to improve vaccine efficacy in these high risk groups we propose to determine if delivery of influenza vaccine through the skin of the young and aged can confer improved immune responses and protection when compared to intramuscular immunization. We plan to build on our preliminary data and previous studies, and take advantage of our extensive experience with different types of microneedle designs and technologies and unique animal models to successfully complete this project. We are motivated by our findings that skin microneedle delivery of existing FDA-approved influenza vaccine formulations can enhance the immune responses in animal models and confer improved protection when compared to intramuscular immunization in the young and aged. Thus, our research has the potential to suggest new vaccination approaches and immunization strategies that will impact and improve public health globally.